rimonabant (SR141716)

DRUG16 trials

Sponsors

Sanofi

Conditions

Coronary AtherosclerosisDiabetes Mellitus, Non-Insulin-DependentDyslipidemiaEating DisordersMaintenance of Smoking CessationObesityObesity in DiabetesSmoking Cessation

Phase 2

Japanese Dose-Response Study of Rimonabant in Obese Patients

CompletedNCT00459004

Start: 2004-10-31End: 2006-04-30Updated: 2009-04-07

Phase 3

Obese Patients With or Without Comorbidities (RIO-North America)

CompletedNCT00029861

SanofiObesity, Weight Loss

Start: 2001-08-31End: 2004-04-30Updated: 2009-04-20

Obese Patients With Untreated Dyslipidemias

CompletedNCT00029835

SanofiDyslipidemia, Obesity

Start: 2001-09-30End: 2003-11-30Updated: 2009-04-20

Obese Patients With Type 2 Diabetes

CompletedNCT00029848

SanofiDiabetes Mellitus, Non-Insulin-Dependent, Obesity, Obesity in Diabetes

Start: 2001-10-31End: 2004-05-31Updated: 2009-04-20

STRADIVARIUS (Strategy To Reduce Atherosclerosis Development InVolving Administration of Rimonabant - the Intravascular Ultrasound Study)

CompletedNCT00124332

SanofiCoronary Atherosclerosis

Start: 2005-01-31End: 2007-10-31Updated: 2009-04-20

An International Study of Rimonabant in Dyslipidemia With AtheroGenic Risk In Abdominally Obese Patients

CompletedNCT00239967

SanofiDyslipidemia, Obesity

Start: 2005-05-31End: 2007-02-28Updated: 2009-04-07

Study Evaluating Rimonabant Efficacy in Drug-NAive DiabEtic Patients

CompletedNCT00257257

SanofiType 2 Diabetes Mellitus

Start: 2005-03-31End: 2006-06-30Updated: 2009-04-20

Study Evaluating Rimonabant Efficacy in Insulin-Treated Diabetic Patients(ARPEGGIO)

CompletedNCT00288236

SanofiType 2 Diabetes Mellitus

Start: 2006-01-31End: 2007-07-31Updated: 2009-04-07

Study of Weight-Reducing Effect and Safety of Rimonabant In Obesity in ASIA (RIO-ASIA)

CompletedNCT00325546

Start: 2006-04-30End: 2007-04-30Updated: 2009-04-07

Rimonabant in Obesity Over a 2-Year Duration (RIO-Europe)

CompletedNCT00386061

Start: 2001-10-31End: 2004-06-30Updated: 2009-04-20

Japanese Study of Rimonabant in Obese Patients With Dyslipidemia (VENUS)

TerminatedNCT00434096

Start: 2007-02-28End: 2009-02-28Updated: 2009-07-20

Efficacy and Safety of Rimonabant as an Aid to Maintenance of Smoking Cessation

CompletedNCT00459173

SanofiMaintenance of Smoking Cessation

Start: 2002-11-30End: 2005-09-30Updated: 2009-04-07

Efficacy and Safety of Rimonabant as an Aid to Smoking Cessation With or Without Nicotine Patch

CompletedNCT00458718

SanofiSmoking Cessation

Start: 2004-09-30End: 2005-07-31Updated: 2009-04-20

Efficacy and Safety of Rimonabant on Weight Loss and Frequency of Binge Episodes in Obese Patients

CompletedNCT00481975

SanofiEating Disorders, Obesity

Start: 2004-08-31End: 2005-08-31Updated: 2009-04-07

Efficacy and Safety of Rimonabant With or Without Hypocaloric Diet in Obese Patients

CompletedNCT00481923

Start: 2004-05-31End: 2005-04-30Updated: 2009-04-20

Long-Term Effect of 10 mg Versus 20 mg Rimonabant in Overweight or Obese Patients

TerminatedNCT00678483

SanofiObesity, Weight Loss

Start: 2008-04-30End: 2009-02-28Updated: 2009-06-17

Related Papers

How many unpublished studies? ClinicalTrials.gov (n = 2614 studies): diabetes | Closed Studies | Interventional Studies | Phase 3, 4 | Search Date: Oct 27, 2014

Figshare2014-01-01

Efficacy of rimonabant in obese patients with binge eating disorder.

2012-11-1234 citations

Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial.

2008-04-01276 citations

Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study.

2006-11-01478 citations

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.

2006-02-01816 citations